Advocates took to Capitol Hill last week to brief lawmakers and their staff about the implications the recent CMS policy change may have on patient access to treatments.
Last month, CMS announced that it would begin to allow Medicare Advantage plans to implement step therapy as a negotiation tool for drug prices. The announcement was met with concern as various industry stakeholders, such as the Community Oncology Alliance, the American College of Rheumatology (ACR), and the American Society of Clinical Oncology, all spoke out against the change.
Hosted by the Part B Access for Seniors and Physicians (ASP) Coalition, advocates took to Capitol Hill last week to brief lawmakers and their staff about the implications the policy may have on patient access to treatments covered under the Medicare Part B program.
Read more about how seniors may be impacted by the Medicare policy change.
Providing the physician viewpoint of step therapy during the meeting was Angus Worthing, MD, FACP, FACR, a practicing rheumatologist and chair of the ACR’s government affairs committee. “Far too many of my patients with Medicare prescription drug plans have experienced frustrating delays in getting treatment due to step therapy,” he said. “Expanding step therapy to [Medicare Advantage] plans will only add more people to the list of those who will face difficulties assessing the care prescribed by their physician as the best course of care.”
Lawmakers also heard from Katie Roberts, a patient advocate with the Arthritis Foundation. “As an individual with psoriatic arthritis, I am unfortunately all too familiar with how even seemingly brief delays in treatment can make a crucial difference in a patient’s life… Lawmakers must understand that this policy change will do real harm to individuals with chronic diseases by delaying treatment access at a time when it is most critically needed.”
During the briefing, a representative from Xcenda, a policy research and consulting firm, provided an overview of their recent report that analyzed physicians’ prescribing behavior through the Medicare Part B program. The report, titled “Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?” found that “there is no meaningful correlation between drug payment and utilization, challenging the theory that physicians significantly favor drugs with high add-on payments.”
Though many industry groups have spoken out against the policy change, CMS has remained firm in its decision. The policy change will take effect in January 2019.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Top 5 Most-Read Regulatory Articles of 2024
December 25th 2024In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first interchangeability designations for biosimilars referencing ustekinumab, adalimumab, denosumab, and aflibercept, marking key regulatory milestones in improving patient access to cost-effective treatments.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.